Navigation Links
Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
Date:4/8/2013

ents with deletion 17p.

The FDA Breakthrough Therapy Designation for ibrutinib in CLL patients with deletion 17p was based on data from pre-clinical and clinical studies where ibrutinib as a monotherapy was used to treat patients with this disease. Ibrutinib has the potential to improve the outcome in this serious and life-threatening disease which has a poor prognosis. In addition, Pharmacyclics and Janssen have recently initiated a Phase II study of ibrutinib in patients with CLL deletion 17p, RESONATE™ -17, which is a single-arm, open-label, multi-center trial using ibrutinib as a monotherapy in patients who have deletion 17p and who did not respond to or relapsed after at least one prior CLL treatment (a high unmet need population). The primary endpoint of the study will be overall response rate. This global study opened this year and Pharmacyclics plans to enroll 111 patients worldwide.

About Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia (CLL) is a slow-growing blood cancer that starts in the white blood cells (lymphocytes), most commonly from B-cells. CLL is the second most common adult leukemia. Approximately 16,000 patients in the US are diagnosed each year with CLL. The prevalence of CLL is approximately 113,000 in the US. The disease is a chronic disease of the elderly with an average survival of about 5 years. Patients commonly receive multiple lines of treatment over the course of their disease.

In CLL the genetic mutation 17p deletion occurs when the short arm of chromosome 17 is missing.  Del 17p is associated with abnormalities of a key tumor suppressor gene, TP53, which results in poor response to chemoimmunotherapy and worse treatment outcomes. It occurs in about 7% of treatment naive CLL patients and is estimated to be approximately 20% to 40% of relapsed or refractory patients harboring the mutation.  

About Ibrutinib

Janssen Biotech, Inc. and Pharmacyclics entered a col
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pharmacyclics, Inc. Prices Public Offering of Common Stock
2. Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock
3. Pharmacyclics First to Announce Breakthrough Therapy Designation in Oncology from the U.S. Food and Drug Administration
4. Pharmacyclics Announces Date of Financial Results for Three and Six Months Ended December 31, 2012 and Conference Call
5. Pharmacyclics Reports Fourth Quarter and Full Year Fiscal 2012 Financial Results and Recent Developments
6. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
7. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
8. scPharmaceuticals LLC Announces Strategic Partnership with Sensile Medical to Develop Novel Heart Failure Treatment Aimed to Reduce Readmission Rates
9. Hanger, Inc. Announces First Quarter 2013 Earnings Release And Conference Call
10. Sigma-Aldrich Announces Q1 2013 Earnings Conference Call
11. Uroplasty Announces CEO Resignation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today ... the second quarter ending June 30, 2015. ... organization.  We are excited to be near the completion ... conducted with topline results expected in the fourth quarter," ... Therapeutics, Inc. "Translarna is now commercially available in 12 ...
(Date:7/30/2015)... 30, 2015 Tianyin Pharmaceutical Inc. (NYSE Amex: ... specializes in the patented biopharmaceutical, modernized traditional Chinese medicine ... updates regarding the notice it received on May 21, ... that the Company was below certain of the Exchange,s ... and 1101 of the NYSE MKT Company Guide, due ...
(Date:7/30/2015)... LAKE, N.J. , July 30, 2015 ... simultaneously in the United States , ... the FDA, EMA and MHLW, respectively) for eribulin, for ... (STS) who have received prior chemotherapy for advanced or ... based on data from a pivotal global Phase 3 ...
Breaking Medicine Technology:PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 10TPI Provides Update Regarding Non-Compliance with NYSE MKT Continued Listing Requirements 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5
... OXNARD, Calif., March 30, 2011 HealthSport, Inc. (OTC ... formulator, developer and manufacturer of dissolvable bi-layer oral thin ... ingredients through buccal absorption, announced today it has signed ... assets of SMI Manufacturing from RT Holdings, LLC.  HealthSport,s ...
... FHI has been selected as one of six ... consortium of 14 global health Product Development Partnerships (PDPs). ... deliver affordable treatments and vaccines that will help improve ... people. FHI,s forty years of research experience ...
Cached Medicine Technology:HealthSport Signs Letter of Intent to Acquire "Excellent" Rated cGMP Certified Nutraceutical Manufacturing Plant 2HealthSport Signs Letter of Intent to Acquire "Excellent" Rated cGMP Certified Nutraceutical Manufacturing Plant 3FHI Selected as Preferred Provider to a Consortium of Product Development Partnerships 2
(Date:8/2/2015)... ... August 03, 2015 , ... A new Phase I research study is looking ... is led by Kenneth G. Lucas, M.D. , chief of the division of ... colleagues at Kosair Children’s Hospital and in the UofL Department of ...
(Date:8/2/2015)... ... August 02, 2015 , ... ... the supportive muscles and connective tissues of a woman’s pelvic organs (uterus, ... damage include straining, heavy lifting, obesity, constipation, multiple vaginal deliveries, genetics, smoking, ...
(Date:8/1/2015)... ... August 02, 2015 , ... AlignLife Office Coordinator Heather ... continuity of care for patients at this natural health care center in Winamac. , ... Mary Heal said. "Heather's role is vital to our approach because we want to ...
(Date:8/1/2015)... ... August 01, 2015 , ... Western University of ... profession” that comprises a growing percentage of U.S. physicians, and reflects the diversity ... one part of the message delivered by John W. Becher, DO, president of ...
(Date:8/1/2015)... ... 01, 2015 , ... The condition where veins are enlarged and gnarled is ... pain and discomfort. Those who spend a lot of time on their feet and ... is doing what it can to create awareness and provide a cure in observance ...
Breaking Medicine News(10 mins):Health News:UofL Physicians Conducting Vaccine Trial for Children with Relapsed Tumors at Kosair Children’s Hospital 2Health News:Minimally Invasive and Robotic Treatment for Pelvic Organ Prolapse Now Available from the Specialists at Women’s Excellence in Bladder Control 2Health News:New Patient Advocate Enhances Natural Health Care 2Health News:COMP-Northwest Welcomes Class of 2019 2Health News:COMP-Northwest Welcomes Class of 2019 3Health News:COMP-Northwest Welcomes Class of 2019 4Health News:COMP-Northwest Welcomes Class of 2019 5Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 2Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 3
... by a group of researchers from Washington University. //The researchers found ... kind of bacteria in their gut that helps to digest food ... same bacteria. ,Humans need efficient bacteria ... to be broken down and the bacteria in obese people ...
... continues with gusto into the 21st century. The search has ... appeal. The latest from scientists from Pittsburgh is that the ... living cell gets damaged, it may advance the aging process ... is too weak to help itself to rejuvenate and repair ...
... of measles were reported from across the U.S of which 34 ... 17 year old girl, who had travelled to// Romania sans vaccination ... highly contagious infection characterised by typical rashes ,and fever was ... interacted with her upon her return to the U.S after her ...
... and a positive mind set play a significant role in ... Research Campaign.// ,During the experiment, pain was first ... later were led to expect reduced pain after the application ... , The results suggest : faith in a Doctor or ...
... to offer Gardasil, to developing countries at affordable rates.// ... Human Papilloma Virus, that is insinuated to cause the ... cancer is rampant in developing countries.80% of deaths attributed to ... ,A single dose of Gardasil is priced at 120 ...
... are registering men with advanced prostate cancer //for a ... of Calcitriol, a naturally occurring active form of vitamin ... specially formulated high-dose vitamin D, taken in combination with ... and improve quality of life in men with advanced ...
Cached Medicine News:Health News:Intestinal Bacteria Blamed for Rotund Figures 2Health News:Clues to Allay Aging 2Health News:Missed Vaccination Caused Largest Measles Outbreak in U.S in 2005 2Health News:Role Of Faith In Healing Process 2
For the quantitative in vitro determination of Alanine Aminotransferase (ALT) in serum and plasma....
... Anteroir Cervical System, in conjunction with adjunctive ... collar), is intended for use in single ... as a means to maintain the relative ... This device is not intended to be ...
The Tag-It™ Cystic Fibrosis ASR reagents can be used by high complexity CLIA approved laboratories for detection of up to 70 mutations and 6 variants (polymorphisms) in the cystic fibrosis tran...
The Tag-It™ Cystic Fibrosis ASR reagents can be used by high complexity CLIA approved laboratories for detection of up to 70 mutations and 6 variants (polymorphisms) in the cystic fibrosis tran...
Medicine Products: